BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32594230)

  • 1. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
    Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
    Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
    Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
    Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
    Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
    Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 8. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
    Jin C; Hacking S; Liang S; Nasim M
    Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
    Lee KS; Yun S; Lee K; Moon S; Choe G
    Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
    Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
    Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.
    Ida N; Nakamura K; Saijo M; Nasu A; Yoshino T; Masuyama H; Yanai H
    Pathol Res Pract; 2021 Apr; 220():153383. PubMed ID: 33676104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
    Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
    Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
    Tober JM; Halske C; Behrens HM; Krüger S; Röcken C
    Hum Pathol; 2019 Dec; 94():98-109. PubMed ID: 31704366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
    Crumley S; Kurnit K; Hudgens C; Fellman B; Tetzlaff MT; Broaddus R
    Mod Pathol; 2019 Mar; 32(3):396-404. PubMed ID: 30291344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
    Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
    Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.